Prothena

Roche's Phase IIb PADOVA study on prasinezumab for early-stage Parkinson's showed potential in delaying motor progression, especially in levodopa-treated patients, with positive trends in secondary endpoints. Prasinezumab was well-tolerated, with no new safety concerns. Roche plans further evaluation and collaboration with health authorities for next steps.

Roche's Phase IIb PADOVA study on prasinezumab for early-stage Parkinson's disease showed potential in delaying motor progression, with positive trends in secondary endpoints. Prasinezumab was well-tolerated, with no new safety concerns. Roche plans further evaluation and collaboration with health authorities to determine next steps.

Roche's Phase IIb PADOVA study on prasinezumab for early-stage Parkinson’s disease showed potential clinical efficacy with a HR=0.84, missing statistical significance. Positive trends were observed in secondary endpoints, especially in patients on levodopa. Prasinezumab was well tolerated with no new safety signals. Roche plans further evaluation and collaboration with health authorities.

Roche's Phase IIb PADOVA study on prasinezumab for early-stage Parkinson’s disease showed potential clinical efficacy with a HR=0.84, missing statistical significance. Positive trends in secondary endpoints were observed, especially in levodopa-treated patients. Prasinezumab was well tolerated, with no new safety signals. Roche plans further data evaluation and collaboration with health authorities.

Roche's Phase IIb PADOVA study on prasinezumab for early-stage Parkinson’s showed potential clinical efficacy with a HR=0.84, missing statistical significance. Positive trends in secondary endpoints were observed, especially in levodopa-treated patients. Prasinezumab was well-tolerated with no new safety signals. Roche plans further evaluation and collaboration with health authorities.

The Phase IIb PADOVA study on prasinezumab for early-stage Parkinson’s disease showed potential clinical efficacy in delaying motor progression, with positive trends in secondary endpoints. Prasinezumab was well-tolerated, with no new safety concerns. Genentech plans further evaluation and collaboration with health authorities to determine next steps.

The Phase IIb PADOVA study on prasinezumab for early-stage Parkinson's showed potential in delaying motor progression, with positive trends in secondary endpoints. It was well-tolerated with no new safety concerns. Genentech plans further evaluation and collaboration with health authorities to determine next steps.

Genentech's Phase IIb PADOVA study on prasinezumab for early-stage Parkinson’s disease missed the primary endpoint but showed potential benefits in delaying motor progression and positive trends in secondary endpoints. The treatment was well-tolerated with no new safety concerns. Further evaluation and collaboration with health authorities are planned.

UCB and Novartis' minzasolmin, an oral alpha-synuclein misfolding inhibitor, failed to meet primary and secondary endpoints in a phase 2a Parkinson’s trial. The study involved 496 early-stage patients, with no new safety risks identified. UCB terminated the program's extension phase but continues analyzing biomarker data. Other companies also target alpha-synuclein, with mixed results.

UCB's minzasolmin, partnered with Novartis, failed in a phase 2a trial for Parkinson's, missing primary and secondary endpoints. The trial involved 496 early-stage patients. UCB terminated the extension phase, analyzing biomarker data. Despite setbacks, UCB continues exploring alpha-synuclein pathology with UCB7583 and another Parkinson's candidate, glovadalen, in phase 2 trials.